Epigenetic biomarker and uses therefor

Patent metadata

Field	Value
Publication number	US-12404540-B2
Application number	US-201917286379-A
Country	US
Kind code	B2
Filing date	Oct 17, 2019
Priority date	Oct 17, 2018
Publication date	Sep 2, 2025
Grant date	Sep 2, 2025

Abstract

Disclosed is an epigenetic biomarker that comprises clustered methylated genomic DNA which can self-assemble to form complexes that have distinct physicochemical properties relative to genomic DNA that lacks such clusters. Also disclosed are methods, systems, compositions and kits that takes advantage of these physicochemical properties for detecting clustered methylated genomic DNA including for determining likelihood of the presence of cancer.

First claim

What is claimed is:

1. A method for detecting and measuring cancer DNA, the method comprising:
exposing endogenous cancer DNA from a biological sample to a working electrode that comprises an electro-conductive material;
applying a potential to the working electrode; and
detecting an electrical signal from the working electrode that is indicative of adsorption of the endogenous cancer DNA to the electro-conductive material, wherein the electrical signal from the working electrode is different than another electrical signal generated from the working electrode when exposed to (1) one corresponding non-cancer DNA or (2) a total amount of endogenous cancer DNA from another biological sample that is different than a total amount of the endogenous cancer DNA from the biological sample.

2. The method of claim 1 , wherein the electro-conductive material is selected from the group consisting of gold, platinum, palladium, silver, carbon, alloys thereof, and composites thereof.

3. The method of claim 1 , wherein the electrical signal is selected from the group consisting of differential pulse voltammetry (DPV), cyclic voltammetry (CV), Linear Sweep Voltammetry (LSV), Square Wave Voltammetry (SWV), chronoamperometry, Electrochemical Impedance Spectroscopy (EIS), current, voltage, impedance, capacitance, charge, conductivity, resistance, and a combination thereof.

4. The method of claim 1 , wherein the biological sample comprises a biological fluid.

5. The method of claim 4 , wherein the biological fluid is selected from the group consisting of whole blood; lysed whole blood; serum; plasma; urine; sputum; sweat; follicular fluid; synovial fluid; amniotic fluid; a nasopharyngeal aspirate; a bronchial aspirate; semen; and cerebrospinal fluid.

6. The method of claim 1 , wherein the endogenous cancer DNA is selected from the group consisting of cellular genomic DNA (cellular gDNA), cell-free DNA (cfDNA), circulating tumor DNA (ctDNA), and extracellular vesicular DNA (evDNA).

7. The method of claim 1 , wherein the endogenous cancer DNA is derived from a subject that has been exposed to a treatment to treat a cancer.

8. The method of claim 7 , further comprising comparing the electrical signal to a threshold.

9. The method of claim 8 , wherein the threshold comprises a reference electrical signal that is indicative of a level of the cancer within the subject before the subject is exposed to the treatment.

Assignees

• Univ Queensland

Inventors

• Sina Abu
• Trau Matt
• Garcia Carrascosa Laura

Classifications

• C12Q2600/154

  Methylation markers · CPC title

• C12Q1/6886 Primary

  for cancer (immunoassay for cancer G01N33/575) · CPC title

• C12Q1/6825

  Nucleic acid detection involving sensors · CPC title

• C12Q1/6809 Primary

  Methods for determination or identification of nucleic acids involving differential detection · CPC title